Media & literature
For those who would like to read more about (scientific) research into KAP, we have placed links below to articles published in professional journals.
Literature & podcasts
Client stories – recovery stories
Directors Rutger and Shiva, along with a former client, discuss treatment at Senz. Want to learn more about Senz’s approach? Listen to this podcast!
An article from the professional journal ‘De Psycholoog’ for psychologists in which a former KAP client of Senz, clinical psychologist Jasper – one of Senz’s KAP therapists – and a researcher from UMC Groningen discuss KAP treatment.
If you want to know more about Senz and/or KAP, listen to the Podcast on Spotify with Karlijn Kindt called: De Alpacast
Engels et al., De Psycholoog, 2024
This article is a review of the developments of psychedelics – specifically ketamine – treatments for the treatment of mental disorders. In this article we argue for embedding psychedelics in psychotherapeutic treatment programs, provided by BIG-registered professionals.
› Read article
This article is a review of the developments of psychedelics – specifically ketamine – treatments for the treatment of mental disorders. In this article we argue for embedding psychedelics in psychotherapeutic treatment programs, provided by BIG-registered professionals.
› Read article
Bahji et al. Expert Opinion on Drug Safety, 2022
This article concerns a systematic literature review that included 36 relevant studies (n=2903) of randomized controlled trials (RCTs) examining the difference in treatment effect of racemic ketamine or esketamine in patients with unipolar or bipolar depression.
› Read article
This article concerns a systematic literature review that included 36 relevant studies (n=2903) of randomized controlled trials (RCTs) examining the difference in treatment effect of racemic ketamine or esketamine in patients with unipolar or bipolar depression.
› Read article
Alnefeesi et al. Journal of Psychiatric Research, 2022
Ketamine is a promising treatment for treatment-resistant depression (TRD) with proven rapid effects according to studies, but results vary per patient. A review (meta-analysis) of 79 studies shows that ketamine can be effective even in repeated treatments, even in patients with severe depression.
› Read article
Ketamine is a promising treatment for treatment-resistant depression (TRD) with proven rapid effects according to studies, but results vary per patient. A review (meta-analysis) of 79 studies shows that ketamine can be effective even in repeated treatments, even in patients with severe depression.
› Read article
Dore et al. Journal of Psychoactive Drugs, 2019
Data from clinical practice (n = 235) show that Ketamine Assisted Psychotherapy (KAP), which combines ketamine with psychotherapy, is effective in reducing depression and anxiety, especially in older patients and those with severe symptoms.
› Read article
Data from clinical practice (n = 235) show that Ketamine Assisted Psychotherapy (KAP), which combines ketamine with psychotherapy, is effective in reducing depression and anxiety, especially in older patients and those with severe symptoms.
› Read article
Bahji et al. Journal of Affective Disorders, 2021
A systematic review and meta-analysis of 24 studies (n = 1877) found that intravenous racemic ketamine is more effective than intranasal esketamine in the treatment of depression, with higher response and remission rates and lower dropout rates.
› Read article
A systematic review and meta-analysis of 24 studies (n = 1877) found that intravenous racemic ketamine is more effective than intranasal esketamine in the treatment of depression, with higher response and remission rates and lower dropout rates.
› Read article
Smith-Apeldoorn et al., Lancet Psychiatry, 2022
Ketamine maintenance therapy shows promise for prolonging antidepressant effects in treatment-resistant depression, with evidence for efficacy across multiple routes of administration including intravenous, intranasal, and oral. Although serious adverse events appear rare, further research with large-scale, long-term studies is needed to determine the safety and place of this treatment in clinical practice.
› Read article
Ketamine maintenance therapy shows promise for prolonging antidepressant effects in treatment-resistant depression, with evidence for efficacy across multiple routes of administration including intravenous, intranasal, and oral. Although serious adverse events appear rare, further research with large-scale, long-term studies is needed to determine the safety and place of this treatment in clinical practice.
› Read article
McIntyre et al., American Journal of Psychiatry, 2021
Ketamine and esketamine offer new treatment options for treatment-resistant depression with a rapid onset of action, while questions remain about their safety and place in treatment guidelines. In this article, an international group of experts discusses the current knowledge and provides practical recommendations for their use in clinical practice, with suggestions for future research.
› Read article
Ketamine and esketamine offer new treatment options for treatment-resistant depression with a rapid onset of action, while questions remain about their safety and place in treatment guidelines. In this article, an international group of experts discusses the current knowledge and provides practical recommendations for their use in clinical practice, with suggestions for future research.
› Read article
